Vaccitech rallies $168m Series B

Vaccitech, a clinical-stage biopharmaceutical company, has raised $168 million in Series B funding.

Vaccitech, a clinical-stage biopharmaceutical company, has raised $168 million in Series B funding. The investors included Future Planet Capital, M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and Oxford Sciences Innovation.

Source: Press Release